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LETTERS TO THE EDITOR 
Natural Killer Cells Express the CD 16 Antigen 
To the Editor: 
We read with great interest and benefit th e recent article from 
Kohchi yama et al [1] conce rnin g immunohistologic studies of 
squamous cell ca rcinoma (SCC). 
The authors suggest a possible parti cipation of Leu-7+ cells as 
antitumo r effector cells against SCc. Moreover, they state that 
anti-Leu-7 monoclonal antibody identifies natural killer (NK) cells. 
This is par tl y in contras t with recent reports from us and o ther 
investigato rs. In fact, light microscopy [2,3] and electron mi-
croscopy [4,5] double-labeling procedures provided evidence for 
the existence of three discrete NK cell subpopulations, i. e., Leu-
r, 11 - , Leu-7 +, 11 +, and Leu-7 - , 11 + cells. The Leu-7 - , 11 + sub-
set possesses the most potent NK cell function capability, whereas 
the Leu-7 +, 11 - subset demonstrates the lowest NK activity [2,3,5]. 
Furthermore, NK cells exp ressing the CD16 (Leu-ll) antigen 
display a different ultras tructural pattern in comparison to Leu-
7 +,11 - cells [6J . Finally , the HNK-l (Leu-7) anti gen is co ex-
pressed by the maj ority of T8, C D11 + suppressor cells [7] . 
The authors describe both OKT8+ and Leu-r cells in close 
associati on with individual cancer cells. Are they the same cells? 
Unfortunately , by using a single labeling, Kohchiyama et al could 
not well characterize the immunophenotype of their Leu-7 + cells. 
In conclusion, it would be necessary to perform double label-
ings to verify to which cell subpopulations the described Leu-7 + 
cells belong. Investigations performed by Kohchiyama et al [1] 
are not sufficient to defin e Leu-7 + cells as NK cells. 
Gian Carlo Manara, M .D. 
Corrado Ferrari, M .D. 
Giuseppe De Panfilis , M .D. 
Department of Dermatology 
University of Parma 
Parma , Italy 
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REPLY 
The authors appreciate Dr. Manara's comments. As was pointed 
out above, we were not able to characterize the Leu-7 + cell sub-
populations, and the possibility cannot fully be denied that the 
OKT8 + cell s also expressed the Leu7 antigen . Although both 
O KT8 + and Leu-7 + cells could be seen in close association with 
individual cancer cells, a difference could be seen in their distri-
bution by careful observation of serial sections. So we believe 
that the OKT8 + and Leu-7 + cells were not the same cells. We 
intend to verify the Leu-7 + cell subpopulations in lesions ofSCC 
in the future. 
Akira Kohchiya ma, M .D. 
Kawasaki Medical School 
Okayama, Japan 
Keratinocyte Grafting: Covering of Skin Defects by Separated Autologous 
Keratinocytes in a Fibrin Net 
To the Editor: 
T he clinica l application of autografts by cultured keratinocytes 
was first demonstra ted in 1981 [1]. We read with great interes t 
the article by T akashima et al in the May 1986 issue . The authors 
reported in connection with an animal model that freshly isolated 
epidermal cells transplanted onto full-thickness wound beds form ed 
a multilayered epithelial structure after 10 days [2]. On the basis 
of this observation, we have developed a method, keratinocyte 
graftin g (KG), for the autotransplantation of skin defects with 
living keratinocytes. A fibrin net is an important element in the 
healing of wounds, as it provides a provisional matrix fo r epi-
dermal cell migration during reepithelializa tion [3,4]. Keratino-
cyte graftin g was therefore carried out with an artifi cial fibrin net 
containing living kera tinocytes. 
Epidermal cells were separated from a fresh surgical skin spec-
imen of the patient by the trypsin digestion method described by 
Eisinger et al [5]. The cells were washed 3 times in phosphate 
basal solution (PBS; 0.05 M phosphate buffer , pH 7.2, and 0. 1 M 
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Table I. The Resul ts of Keratin ocy te G raftin g 
G raftin g w ith 
Keratinocytes in fib rin nct 
Keratinocy tes in PBS 
Beriplast (cont ro l) 
n 
10 
5 
5 
Improved 
Epitheliali za tion 
8 
1 
o 
PBS = 0.05 M phosphate burrer, pH 7.2, and 0. 1 M sodiulll chloride . 
sodium chlo ride) and res uspended in the fibrin ogen component 
of a hi ghl y concentrated fibrino gen preparation fo r tiss ue sti ckin g 
(Beripl as t, Behrin g). Such suspensions co ntained 70-80% viable 
keratinocytes. Fina ll y, the keratinocyte-fibrinogen suspension (1-8 
X 10(' ce ll s/ ml) was acti va ted by the Ca + + and thro mbin com-
ponents of Beripl as t to form a fibrin net o n th e granul ation tissue 
of th e recipient sur face. 
When KG was used , co mplete epithelializa tion was observed 
w ithin 2 weeks in 8 of 10 patients sufferin g from chro ni c sk in 
defects . Keratinocytes in PBS or fibrino gen (Beriplas t) fail ed to 
improve ep ithelializa tion (Table I). 
As compared w ith tran splantation with cultured skin equi va-
lents, the KG method h a~ so me adva ntages . (1) Multipli cation of 
keratinocytes in vitro is not necessary if the surface area of the 
wound is smaller than 5 cm2 (2) A sufficie nt number o f cells ca n 
be o btained for transplantati on in a sho rter time. (3) In the near 
fut ure it w ill be possible to set up kcratin ocy te cel l banks o f deep-
frozen HLA typed cul tured keratinocy tes. Accordin gly, we be-
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lieve th at the KG method mi g ht be an important step to w ard the 
auto trans plantation of large body surfaces w ith in vitro cultured 
keratinocytes. 
J i nos Hun ya di , M .D. 
Bea tri x Farkas, M .D. 
Ca mill o Bertcnyi, M . D . 
Judit Olah , M .D. 
Attila Dobozy, M . D. 
Depa rtment of D ermato logy 
Uni versity M edica l School 
Szeged , Hun ga ry 
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Announcelnent of the National Epidermolysis Bullosa Registry 
To the Editor: 
T he Laborato ry for In ves tigative Derm atology at The Rockefeller 
Uni vers ity was recentl y awa rd ed a 5-yea r contract by the N ationa l 
Institute of Arthriti s and Muscul os keleta l and Skin Diseases 
(NIAM S), to esta blish a N atio nal E pidermolysis Bu ll osa (EB) 
Reg istry. The Registry, which is headed by D . M artin Ca rter, 
M .D., co mprises a Data Coordin atin g Center (DCC), which is 
based at The Rockefeller Uni ve rsity Hospita l, fo ur geographica ll y 
dispersed C linica l Centers, and a Steering Committee. The DCC 
is responsible for the overa ll o perations of the Registry. The 
C linical Centers are headed by Drs . E . A. Bauer at the Wash-
ing ton Uni vers ity School of Med icine in St. Louis, J. D . Fine at 
the University of Alabama in Birmingham , V. P. Sybert at the 
Uni versity of Washington School o f Med icine in Seattle, and D . 
M. Ca rter in New York. These C lini cal Centers are respon sible 
fo r patient enro llment in th eir cachement areas, patient exami-
nations, and transmittin g inform atio n to th e DCC. The Steering 
Committee wi ll serve in an advisory capacity and w ill include 
scientists, clinicians, and laypersons. The Dystro phic Ep ider-
mo lysis Bullosa Resea rch Association of A merica (DEBRA) , a 
no nprofit vo luntary o rga ni za tion th at promotes EB research and 
provides informati on and suppo rt to afAi cted patients and their 
fa milies, will also parti cipate in Registry activities. 
The Registry wi ll co llect appropriate epidemiologic info rm a-
tion about EB, provide statisti ca l and geneti c informatio n , and 
assess th e econo mic and social impact of EB , while develo ping a 
roster of well-characterized patients w ho are willin g to participate 
in vario us research projects. 
We are committed to develo ping a first-rate Registry, one that 
wi ll at trac t th e interes t and participatio n o f patients, scienti sts , 
and clinicians aro und the wo rld. We ask all o f o ur coll eagues in 
dermatology to assist in the Registry. Correspondence from phy-
sicians and scientists w ho are awa re o f patients w ith EB is invited. 
D . M artin Ca rter, M .D. 
Laborato ry for In vestiga tive Derm ato logy 
The Rockefeller University 
1230 York A venue 
N ew Yo rk , N ew Yo rk 10021-6399 
